SG11201806623VA - Bacteria over-expressing c-di-amp and therapeutic methods - Google Patents

Bacteria over-expressing c-di-amp and therapeutic methods

Info

Publication number
SG11201806623VA
SG11201806623VA SG11201806623VA SG11201806623VA SG11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA SG 11201806623V A SG11201806623V A SG 11201806623VA
Authority
SG
Singapore
Prior art keywords
international
maryland
baltimore
mycobacterium
pct
Prior art date
Application number
SG11201806623VA
Inventor
William R Bishai
Ruchi Jain Dey
Bappaditya Dey
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Publication of SG11201806623VA publication Critical patent/SG11201806623VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/04Mycobacterium, e.g. Mycobacterium tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/130616 Al 18 August 2016 (18.08.2016) WIPO I PCT 11111111111111 0 11101 010 11111 0111 11111 01110111 01111101E11011 111111111111111 0111111 (51) International Patent Classification: A61K 39/04 (2006.01) A61K 48/00 (2006.01) A61K 35/74 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2016/017248 (22) International Filing Date: 10 February 2016 (10.02.2016) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/114,610 11 February 2015 (11.02.2015) US (71) Applicant: THE JOHNS HOPKINS UNIVERSITY [US/US]; 3400 N. Charles Street, Baltimore, Maryland 21218 (US). (72) Inventors: BISHAI, William R.; 1202 Ridervale Road, Baltimore, Maryland 21204 (US). DEY, Ruchi Jain; 6316 Greenspring Ave., Apt. 208, Baltimore, Maryland 21209 (US). DEY, Bappaditya; 6316 Greenspring Ave., Apt. 208, Baltimore, Maryland 21209 (US). (74) Agent: FEULNER, Gregory; 100 N. Charles Street, 5th Floor, Baltimore, Maryland 21201 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) W O 20 16/ 1306 16 Al (54) Title: BACTERIA OVER-EXPRESSING C-DI-AMP AND THERAPEUTIC METHODS (57) : The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobac- terium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a my - cobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.?
SG11201806623VA 2015-02-11 2016-02-10 Bacteria over-expressing c-di-amp and therapeutic methods SG11201806623VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562114610P 2015-02-11 2015-02-11
PCT/US2016/017248 WO2016130616A1 (en) 2015-02-11 2016-02-10 Bacteria over-expressing c-di-amp and therapeutic methods

Publications (1)

Publication Number Publication Date
SG11201806623VA true SG11201806623VA (en) 2018-09-27

Family

ID=56615726

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806623VA SG11201806623VA (en) 2015-02-11 2016-02-10 Bacteria over-expressing c-di-amp and therapeutic methods

Country Status (4)

Country Link
US (3) US10130663B2 (en)
CA (1) CA3013713A1 (en)
SG (1) SG11201806623VA (en)
WO (1) WO2016130616A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3013713A1 (en) * 2015-02-11 2016-08-18 The Johns Hopkins University Bacteria over-expressing c-di-amp and therapeutic methods
EP3402498A1 (en) 2016-01-11 2018-11-21 Synlogic, Inc. Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
BR112019013863A2 (en) * 2017-01-06 2020-03-03 Synlogic Operating Company, Inc. MICRO-ORGANISMS PROGRAMMED TO PRODUCE IMMUNE AND ANTICANCER THERAPEUTIC MODULATORS IN TUMOR CELLS
CN111246865A (en) * 2017-07-12 2020-06-05 同生运营公司 Microorganisms programmed to produce immunomodulators and anticancer therapeutics in tumor cells
JP2021512144A (en) * 2018-01-26 2021-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニアThe Regents of the University of California Intranasal delivery of tuberculosis vaccine containing cyclic dinucleotide adjuvant
CN112601535A (en) * 2018-04-17 2021-04-02 约翰霍普金斯大学 Recombinant therapeutic intervention for cancer
CA3194581A1 (en) * 2020-10-01 2022-04-07 Alok Singh Bcg based vaccine compositions and methods of use thereof
CN112342233B (en) * 2020-11-10 2022-08-26 上海陶宇晟生物技术有限责任公司 Polynucleotide for increasing c-di-AMP production when bacteria express DacA

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002026819A2 (en) * 2000-09-26 2002-04-04 Roger Williams Hospital Recombinant bcg vaccines for the prevention and treatment of cancer
US9061048B2 (en) * 2010-12-15 2015-06-23 The Regents Of The University Of California Cyclic di-AMP induction of type I interferon
WO2013040548A2 (en) 2011-09-17 2013-03-21 Yale University Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
WO2013066264A1 (en) 2011-10-31 2013-05-10 Nanyang Technological University Enzymatic synthesis of cyclic and linear diadenosine monophosphate
JP5650780B2 (en) 2012-04-04 2015-01-07 日東電工株式会社 Vaccine composition
EP2858722B8 (en) * 2012-06-08 2018-02-21 Aduro BioTech, Inc. Compostions and methods for cancer immunotherapy
BR112015013440B1 (en) 2012-12-13 2020-12-08 Aduro Biotech, Inc compositions comprising cyclic purine dinucleotides with stereochemistry
JP6512567B2 (en) 2013-02-05 2019-05-15 日東電工株式会社 WT1 peptide cancer vaccine composition for transdermal administration
US10076491B2 (en) 2013-02-05 2018-09-18 Nitto Denko Corporation Vaccine composition
CA2840978A1 (en) 2013-02-05 2014-08-05 Nitto Denko Corporation Vaccine composition for mucosal administration
JP6497691B2 (en) 2013-02-05 2019-04-10 日東電工株式会社 WT1 peptide cancer vaccine composition for mucosal administration
JP6453855B2 (en) 2013-05-18 2019-01-16 アドゥロ バイオテック,インク. Compositions and methods for activating "interferon gene stimulator" dependent signaling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CA3013713A1 (en) * 2015-02-11 2016-08-18 The Johns Hopkins University Bacteria over-expressing c-di-amp and therapeutic methods
DK3317301T3 (en) 2015-07-29 2021-06-28 Immutep Sas COMBINATION THERAPIES INCLUDING ANTIBODY MOLECULES AGAINST LAYER-3
CN105367617A (en) 2015-09-25 2016-03-02 武汉品生科技有限公司 Derivative based on c-di-AMP, tat polypeptide and application of derivative in inhibitor in type I interferon micromolecules
BR112018008339A2 (en) 2015-10-28 2018-10-30 Aduro Biotech Inc compositions and methods for activating interferon gene-dependent signaling enhancer
CN106554416B (en) 2015-12-09 2019-03-15 聊城市奥润生物医药科技有限公司 A kind of application of anti-PD-L1 Humanized monoclonal antibodies joint interferon gene stimulates the protein (STING) agonist in antitumor
CN106539814A (en) 2015-12-09 2017-03-29 聊城市奥润生物医药科技有限公司 Interferon gene stimulatory protein(SP)(STING)Application of the agonist in the diseases such as resisting rheumatoid arthritis
WO2017106740A1 (en) 2015-12-16 2017-06-22 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
EP3448397A4 (en) 2016-04-26 2020-01-08 Qu Biologics Inc. Therapeutically triggering an innate immune response in a target tissue
CN106539816A (en) 2016-04-30 2017-03-29 聊城市奥润生物医药科技有限公司 Application of the ring dinucleotides in preventing and treating multiple sclerosis
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
NL2017267B1 (en) 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018026717A1 (en) 2016-08-01 2018-02-08 Aduro Biotech, Inc. Protein expression enhancer sequences and use thereof
WO2018030457A1 (en) 2016-08-10 2018-02-15 武田薬品工業株式会社 Method for modifying target site in genome of eukaryotic cell, and method for detecting presence or absence of nucleic acid sequence to be detected at target site
CN112601535A (en) * 2018-04-17 2021-04-02 约翰霍普金斯大学 Recombinant therapeutic intervention for cancer

Also Published As

Publication number Publication date
US10130663B2 (en) 2018-11-20
US20190030091A1 (en) 2019-01-31
CA3013713A1 (en) 2016-08-18
US20180028577A1 (en) 2018-02-01
US10842828B2 (en) 2020-11-24
US11590177B2 (en) 2023-02-28
US20210145896A1 (en) 2021-05-20
WO2016130616A1 (en) 2016-08-18

Similar Documents

Publication Publication Date Title
SG11201806623VA (en) Bacteria over-expressing c-di-amp and therapeutic methods
SG11201803906PA (en) Control of cellular redox levels
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201900269XA (en) Channel sensing for independent links
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201807573VA (en) Methods for providing single-stranded rna
SG11201808990QA (en) Compositions for topical application of compounds
SG11201810179RA (en) Novel crispr enzymes and systems
SG11201804384UA (en) Geometric configurations for gastric residence systems
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201805072PA (en) Nicotine powder delivery system
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201809341PA (en) Mobile robot
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201909837YA (en) Methods for treating lung disorders
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201901389XA (en) Combination therapy with glutaminase inhibitors
SG11201810196RA (en) Cancer treatments